JPMorgan Chase & Co. cut shares of Endologix (NASDAQ:ELGX) from a neutral rating to an underweight rating in a research report report published on Tuesday, January 2nd, MarketBeat reports.
Other equities analysts have also issued reports about the company. Canaccord Genuity reissued a hold rating and set a $5.00 price target on shares of Endologix in a research report on Wednesday, November 8th. Piper Jaffray Companies reissued an overweight rating on shares of Endologix in a research report on Tuesday, December 12th. ValuEngine downgraded Endologix from a sell rating to a strong sell rating in a research note on Sunday, December 31st. Royal Bank of Canada restated a hold rating and set a $5.00 price objective on shares of Endologix in a research note on Tuesday, October 3rd. Finally, BidaskClub cut Endologix from a buy rating to a hold rating in a research note on Friday, December 15th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $5.41.
Shares of Endologix (ELGX) opened at $4.27 on Tuesday. The company has a market capitalization of $354.68, a PE ratio of -4.59 and a beta of 0.72. Endologix has a 52-week low of $4.08 and a 52-week high of $7.66. The company has a debt-to-equity ratio of 2.61, a quick ratio of 2.11 and a current ratio of 2.90.
Endologix (NASDAQ:ELGX) last posted its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.06. Endologix had a negative return on equity of 52.18% and a negative net margin of 41.60%. analysts expect that Endologix will post -0.68 earnings per share for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of ELGX. Schwab Charles Investment Management Inc. increased its holdings in shares of Endologix by 10.5% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 321,309 shares of the medical instruments supplier’s stock valued at $1,562,000 after acquiring an additional 30,429 shares during the last quarter. Rhumbline Advisers grew its holdings in Endologix by 0.4% in the 2nd quarter. Rhumbline Advisers now owns 95,581 shares of the medical instruments supplier’s stock valued at $465,000 after buying an additional 381 shares during the last quarter. Marshall Wace North America L.P. grew its holdings in Endologix by 277.3% in the 2nd quarter. Marshall Wace North America L.P. now owns 173,939 shares of the medical instruments supplier’s stock valued at $870,000 after buying an additional 127,838 shares during the last quarter. Swiss National Bank grew its holdings in Endologix by 14.3% in the 2nd quarter. Swiss National Bank now owns 137,900 shares of the medical instruments supplier’s stock valued at $670,000 after buying an additional 17,300 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its position in shares of Endologix by 11.5% during the 2nd quarter. Alliancebernstein L.P. now owns 108,757 shares of the medical instruments supplier’s stock worth $529,000 after buying an additional 11,200 shares during the period.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.